RE: ...but SG&A expenses are up, mostly due to new hires. Hopefully revenues are lagging this cost increase. Bloody mgmt has been saying for a long time this is a scalable biz but the damn earnings don't grow when revenue does. At the Dec 2019 Piper Jaffray Healthcare Conference Hoyt said with a straight face that the co. was now set up to double patients without increasing corporate costs and shareholders should see bottom line leverage starting in 2020. What a crock of BS.
ol_griz wrote: Revenue beat but .02 eps is sure not going to light the world on fire.